Peter Kenner died very quickly from pancreatic neuroendocrine cancer just two months following his diagnosis. He was in his professional prime as a long-term value investor and enjoyed a full life spending time with our family and many friends. Although he complained of fatigue off and on, he did not display classic symptoms nor did he have any of the typical factors that are associated with increased risk of pancreatic cancer. Peter's sudden diagnosis and subsequent death were an incomprehensible shock and deep personal loss.
Peter's story is all too common. Pancreatic cancer is now the fourth leading cause of cancer-related death in the United States. In the past decade, there has been a 33% increase in the number of pancreatic cancer cases. The overall 5-year relative survival rate of pancreatic cancer is only 6% and has not improved in 50 years. Detection and highest cure rate occur if the diagnosis is made while the tumor is localized to the pancreas. Most tumors are diagnosed at a late stage when the cancer has metastasized, with a dismal 5-year relative survival rate of only 2%. (Surveillance Epidemiology and End Results, SEER Facts Sheets: Pancreas 8/2013, American Cancer Society 2013, National Cancer Institute 2013)
To meet this growing challenge, family and friends established Kenner Family Research Fund in Peter's memory. We invest in innovative initiatives that will lead to the development of an early detection protocol for pancreatic cancer. Our efforts are focused on outcomes that will positively impact the time of diagnosis, the subsequent treatment options, and the quality of life for those individuals diagnosed with this disease.